Logo image of SNOA

SONOMA PHARMACEUTICALS INC (SNOA) Stock Price, Forecast & Analysis

USA - NASDAQ:SNOA - US83558L3033 - Common Stock

3.52 USD
-0.1 (-2.76%)
Last: 11/18/2025, 2:17:06 PM

SNOA Key Statistics, Chart & Performance

Key Statistics
Market Cap5.81M
Revenue(TTM)16.94M
Net Income(TTM)-3.48M
Shares1.65M
Float1.63M
52 Week High6.92
52 Week Low1.75
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.2
PEN/A
Fwd PEN/A
Earnings (Next)02-03 2026-02-03/amc
IPO2007-01-26
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


SNOA short term performance overview.The bars show the price performance of SNOA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20

SNOA long term performance overview.The bars show the price performance of SNOA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40 -60 -80

The current stock price of SNOA is 3.52 USD. In the past month the price decreased by -8.12%. In the past year, price increased by 27.02%.

SONOMA PHARMACEUTICALS INC / SNOA Daily stock chart

SNOA Latest News, Press Relases and Analysis

SNOA Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 47.04 979.10B
JNJ JOHNSON & JOHNSON 19.22 480.56B
MRK MERCK & CO. INC. 10.95 240.92B
PFE PFIZER INC 7.95 144.61B
BMY BRISTOL-MYERS SQUIBB CO 7.19 96.03B
ZTS ZOETIS INC 18.65 52.41B
RPRX ROYALTY PHARMA PLC- CL A 9.6 23.02B
VTRS VIATRIS INC 4.62 12.54B
ELAN ELANCO ANIMAL HEALTH INC 22.36 10.66B
CORT CORCEPT THERAPEUTICS INC 85.84 7.96B
AXSM AXSOME THERAPEUTICS INC N/A 7.41B
CRNX CRINETICS PHARMACEUTICALS IN N/A 4.06B

About SNOA

Company Profile

SNOA logo image Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

Company Info

SONOMA PHARMACEUTICALS INC

5445 Conestoga Court, Suite 150

Boulder COLORADO 30189 US

CEO: Amy Trombly

Employees: 168

SNOA Company Website

SNOA Investor Relations

Phone: 18007599305

SONOMA PHARMACEUTICALS INC / SNOA FAQ

What does SONOMA PHARMACEUTICALS INC do?

Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.


What is the current price of SNOA stock?

The current stock price of SNOA is 3.52 USD. The price decreased by -2.76% in the last trading session.


What is the dividend status of SONOMA PHARMACEUTICALS INC?

SNOA does not pay a dividend.


How is the ChartMill rating for SONOMA PHARMACEUTICALS INC?

SNOA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


How is the market expecting SNOA stock to perform?

7 analysts have analysed SNOA and the average price target is 15.1 USD. This implies a price increase of 328.86% is expected in the next year compared to the current price of 3.52.


What is SONOMA PHARMACEUTICALS INC worth?

SONOMA PHARMACEUTICALS INC (SNOA) has a market capitalization of 5.81M USD. This makes SNOA a Nano Cap stock.


Can you provide the upcoming earnings date for SONOMA PHARMACEUTICALS INC?

SONOMA PHARMACEUTICALS INC (SNOA) will report earnings on 2026-02-03, after the market close.


SNOA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SNOA. When comparing the yearly performance of all stocks, SNOA turns out to be only a medium performer in the overall market: it outperformed 46.11% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SNOA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to SNOA. The financial health of SNOA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SNOA Financial Highlights

Over the last trailing twelve months SNOA reported a non-GAAP Earnings per Share(EPS) of -2.2. The EPS increased by 55.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -25.11%
ROE -91.87%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%45.76%
Sales Q2Q%56.58%
EPS 1Y (TTM)55.3%
Revenue 1Y (TTM)25.02%

SNOA Forecast & Estimates

7 analysts have analysed SNOA and the average price target is 15.1 USD. This implies a price increase of 328.86% is expected in the next year compared to the current price of 3.52.

For the next year, analysts expect an EPS growth of -96.42% and a revenue growth 11.38% for SNOA


Analysts
Analysts85.71
Price Target15.1 (328.98%)
EPS Next Y-96.42%
Revenue Next Year11.38%

SNOA Ownership

Ownership
Inst Owners6.31%
Ins Owners1.28%
Short Float %2.09%
Short Ratio0.67